别名 C-domain 1、C-domain 2、Cachectin + [20] |
简介 Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Up-regulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208). Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line (PubMed:16829952, PubMed:22517918, PubMed:23396208). Induces insulin resistance in adipocytes via inhibition of insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake. Induces GKAP42 protein degradation in adipocytes which is partially responsible for TNF-induced insulin resistance (By similarity). Plays a role in angiogenesis by inducing VEGF production synergistically with IL1B and IL6 (PubMed:12794819). Promotes osteoclastogenesis and therefore mediates bone resorption (By similarity).
The TNF intracellular domain (ICD) form induces IL12 production in dendritic cells. |
靶点 |
作用机制 TNF-α抑制剂 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 日本 |
首次获批日期2023-09-25 |
靶点 |
作用机制 TNF-α抑制剂 |
在研机构 |
原研机构 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 中国 |
首次获批日期2023-06-07 |
开始日期2025-11-29 |
开始日期2025-10-01 |
申办/合作机构- |
开始日期2025-09-18 |
申办/合作机构- |